Approval for generic Ozempic® in Canada strengthens OneSource’s global CDMO footprint in complex peptide injectable manufacturing
The agreement could rise to $900 million if key commercial milestones are met
The litigation involved multiple civil lawsuits alleging anti-competitive practices and violations of federal
The company stated that it will work closely with the regulator to address the observations within the stipulated timeframe
Routine regulatory filing confirms completion of demat and share transfer compliances for March quarter
The acquisition aims to bolster Merck’s hematology portfolio with Terns’ lead oncology candidate, TERN-701
Multi-year CDMO partnership combines AI-led virtual development, precision chemistry and GMP manufacturing to accelerate five high-science APIs across regulated markets
Rs 66 lakh acquisition will support DNA engineering and novel cell-gene therapy alternatives to conventional chemotherapy
The company has highlighted setbacks in Phase II studies while outlining fresh regulatory and late-stage development plans for Fibromun and Nidlegy
Call it a major breakthrough for diagnostic imaging
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
